Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Recruiting · NCT07246564 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 4 | 2026-09-11 | NCT07246564 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| UCB Biopharma SRL | 30 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mg0033 20040 | Beijing | China | 1 |
| Mg0033 20172 | Shanghai | China | 1 |
| Mg0033 20180 | Wuhan | China | 1 |
| Mg0033 20184 | Shenzhen | China | 1 |
| Mg0033 20185 | Jinan | China | 1 |
| Mg0033 20204 | Suzhou | China | 1 |
| Mg0033 20261 | Changchun | China | 1 |
| Mg0033 20269 | Guangzhou | China | 1 |
| Mg0033 20295 | Changsha | China | 1 |
| Mg0033 20347 | Jinan | China | 1 |
| Mg0033 20348 | Fuzhou | China | 1 |
| Mg0033 20349 | Xuzhou SHI | China | 1 |